Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

Key Points

Nab-paclitaxel plus ramucirumab improved patient outcomes compared to solvent-based treatment.
Key evidence showed a statistically significant improvement in overall survival for the experimental group.
This randomized phase 2 trial evaluated the impact of specific biomarkers on treatment efficacy and survival duration.
Findings highlight the need for further studies to validate these results and understand biomarker implications.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Assesses nab-paclitaxel plus ramucirumab efficacy in gastric cancer, indicating potential benefits in treatment.

No takes yet. Share an insight, caveat, or question.

Hirata et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share